US EditionAgora, Inc. Reports First Quarter 2025 Financial Results
- IceCure Medical reported financial results for the quarter ending March 31, 2025, highlighting ongoing developments in its ProSense cryoablation system.
- The report follows the June 2024 FDA authorization of XSense and the recent submission of a post market study plan awaiting FDA approval for early-stage breast cancer treatment.
- ProSense sales grew in North America despite a 2% global sales decline due to decreased sales in Asia, offset by gains in Europe and North America.
- Revenue from ProSense systems and probes was $725,000 this quarter, with net loss narrowing to $3.59 million and research and development expenses decreasing 15%.
- IceCure anticipates FDA marketing authorization, expects further regulatory approvals, and plans publication of additional clinical data, showing continued medical and commercial momentum.
Insights by Ground AI
Does this summary seem wrong?
17 Articles
17 Articles
All
Left
8
Center
3
Right
1
Organto Foods Announces Record First Quarter 2025 Financial Results
TORONTO, ON AND BREDA, THE NETHERLANDS / ACCESS Newswire / May 28, 2025 / Organto Foods Inc. (TSXV:OGO)(OTC PINK:OGOFF)(FSE:OGF) ("Organto" or "the Company"), is pleased to announce its financial results for the three months ended March 31, 2025. All amounts…
Agora, Inc. Reports First Quarter 2025 Financial Results
SANTA CLARA, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Agora, Inc. (NASDAQ: API) (the “Company”), a pioneer and leader in real-time engagement technology, today announced its unaudited financial results for the first quarter ended March 31, 2025.
Coverage Details
Total News Sources17
Leaning Left8Leaning Right1Center3Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
C 25%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
